Look for Drugs and Conditions

Reference pic

Molnupiravir set to be launched in India post-approval by DCGI

DTMT Network

Molnupiravir, the oral anti-COVID drug is set to be launched in India after the Drugs Controller General of India (DCGI) completes its review of clinical data for the treatment of  COVID-19  in adults in  India, a statement released by Sun Pharmaceuticals said.

Sun Pharma will market molnupiravir in India under the brand name Molxvir at an economical price it added.

Earlier, the company had entered into an agreement with Merck Sharpe  Dohme  (MSD) to manufacture and supply molnupiravir in India and to over 100 low and middle-income countries.

Molnupiravir is the first oral antiviral to be approved by the  Medicines and  Healthcare products  Regulatory  Agency of the United Kingdom for the treatment of mild-to-moderate  COVID  in adults and is currently under review by the United States Food and Drug Administration for emergency use authorisation.

“The recent authorisation of molnupiravir, licensed from MSD and Ridgeback, by the UK regulator is a positive step. In line with our consistent efforts to accelerate access to new drugs for COVID-19 treatment, we are gearing up to make Molxvir available to patients and healthcare providers across India at an economical price post-approval by DCGI,” Kirti Ganorkar, CEO of India Business, Sun Pharma said.  

Molxvir will be manufactured at one of our plants in India and we have enough capacity to meet the demand,” he added.

Earlier in a planned interim analysis of the MOVe-OUT phase 3 trial by Merck, molnupiravir was found to reduce the risk of hospitalisation by as much as 50% and was effective against variants like Gamma, Delta, and Mu, the statement added.


0 Comments
Be first to post your comments

Post your comment

Related Articles

Ad 5